Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations

References

• Neumann F-J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87–165.
   PubMed Web of Science ®Google Scholar
• Collet JP, Thiele H, Barbato E, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021 Apr 7;42(14):1289-1367.
   Web of Science ®Google Scholar
• Capodanno D, Alfonso F, Levine GN, et al. ACC/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison. J Am Coll Cardiol. 2018 Dec 11;72(23):2915–2931.
   PubMed Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018 Jan 7;39(2):119–177.
   PubMed Web of Science ®Google Scholar
• Bossavy JP, Thalamas C, Sagnard L, et al. A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans. Blood. 1998 Sep 1;92(5):1518–1525.
   PubMed Web of Science ®Google Scholar
• Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol. 2015 Jan;12(1):30–47.
   PubMed Web of Science ®Google Scholar
• Sibbing D, Aradi D, Alexopoulos D, et al. updated expert consensus statement on platelet function and genetic testing for Guiding P2Y(12) receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interventions. 2019 Aug 26;12(16):1521–1537.
   PubMed Web of Science ®Google Scholar
• Franchi F, Rollini F, Cho JR, et al. Platelet function testing in contemporary clinical and interventional practice. Current treatment opt cardiovascular med. 2014 May;16(5):300.
   PubMedGoogle Scholar
• Buccheri S, Capodanno D, James S, et al. Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms. Expert Opin Drug Saf. 2019 Dec;18(12):1171–1189.
   PubMed Web of Science ®Google Scholar
• Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019 Aug 14;40(31):2632–2653.
   PubMed Web of Science ®Google Scholar
• Ari H, Ozkan H, Karacinar A, et al. The EFFect of hIgh-dose ClopIdogrel treatmENT in patients with clopidogrel resistance (the EFFICIENT trial). Int J Cardiol. 2012 Jun 14;157(3):374–380.
   PubMed Web of Science ®Google Scholar
• Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. The New England Journal of Medicine. 2019;381(17):1621–1631.
   PubMed Web of Science ®Google Scholar
• Collet J-P, Cuisset T, Rangé G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. The New England Journal of Medicine. 2012;367(22):2100–2109.
   PubMed Web of Science ®Google Scholar
• Pereira NL, Farkouh ME, So D, et al. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial. Jama. 2020;324(8):761–771.
   PubMed Web of Science ®Google Scholar
• Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. Jama. 2011 Mar 16;305(11):1097–1105.
   PubMed Web of Science ®Google Scholar
• Sibbing D, Aradi D, Jacobshagen C, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017 Oct 14;390(10104):1747–1757. (London, England).
   PubMed Web of Science ®Google Scholar
• Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. J Am Coll Cardiol. 2012 Jun 12;59(24):2159–2164.
   PubMed Web of Science ®Google Scholar
• Zheng YY, Wu TT, Yang Y, et al. Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial. Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):211–221.
   PubMed Web of Science ®Google Scholar
• Moon JY, Franchi F, Rollini F, et al. Role of genetic testing in patients undergoing percutaneous coronary intervention. Expert Rev Clin Pharmacol. 2018 Feb;11(2):151–164.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Ferreiro JL, Price MJ, et al. Platelet function and genetic testing. J Am Coll Cardiol. 2013 Oct 22;62(17):S21–31.
   PubMed Web of Science ®Google Scholar
• Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation. 2000 Aug 8;102(6):624–629.
   PubMed Web of Science ®Google Scholar
• Trenk D, Hochholzer W. Genetics of platelet inhibitor treatment. Br J Clin Pharmacol. 2014;77(4):642–653. PubMed PMID: 23981082; eng.
   PubMed Web of Science ®Google Scholar
• Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000 Nov;84(11):891–896.
   PubMedGoogle Scholar
• Shuldiner AR, O’Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. Jama. 2009 Aug 26;302(8):849–857.
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354–362.
   PubMed Web of Science ®Google Scholar
• Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. Jama. 2010 Oct 27;304(16):1821–1830.
   PubMed Web of Science ®Google Scholar
• Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009 Jan 22;360(4):363–375.
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol. 2010 Jun 1;55(22):2427–2434.
   PubMed Web of Science ®Google Scholar
• Rehmel JL, Eckstein JA, Farid NA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos. 2006 Apr;34(4):600–607.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Dharmashankar K, Angiolillo DJ. Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Expert Rev Cardiovasc Ther. 2010 Feb;8(2):151–158.
   PubMedGoogle Scholar
• Vang JJ, Nilsson L, Berntsson P, et al. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost. 2009 Sep;7(9):1556–1565.
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol. 2014 Jun 17;63(23):2503–2509.
   PubMed Web of Science ®Google Scholar
• D’Amario D, Restivo A, Leone AM, et al. Ticagrelor and preconditioning in patients with stable coronary artery disease (TAPER-S): a randomized pilot clinical trial. Trials. 2020;21(1):192.
   PubMedGoogle Scholar
• Galli M, Andreotti F, D’Amario D, et al. Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2020 Jan 1;6(1):43–56.
   PubMed Web of Science ®Google Scholar
• Park Y, Franchi F, Rollini F, et al. Dual antiplatelet therapy after coronary stenting. Expert Opin Pharmacother. 2016 Sep;17(13):1775–1787.
   PubMed Web of Science ®Google Scholar
• Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-Segment Elevation. N Engl J Med. 2001;345(7):494–502.
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. Jama. 2002 Nov 20;288(19):2411–2420.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-Segment Elevation. N Engl J Med. 2005;352(12):1179–1189.
   PubMed Web of Science ®Google Scholar
• Addition of clopidogrel to aspirin in. 45852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607–1621.
   PubMed Web of Science ®Google Scholar
• Aradi D, Kirtane A, Bonello L, et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J. 2015 Jul 14;36(27):1762–1771.
   PubMed Web of Science ®Google Scholar
• Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013 Aug 17;382(9892):614–623. (London, England).
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015.
   PubMed Web of Science ®Google Scholar
• Roe MT, Armstrong PW, Fox KAA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367(14):1297–1309.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791–1800.
   PubMed Web of Science ®Google Scholar
• Steg PG, Bhatt DL, Simon T, et al. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019;381(14):1309–1320.
   PubMed Web of Science ®Google Scholar
• Silvain J, Lattuca B, Beygui F, et al. Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. Lancet. 2020;396(10264):1737–1744.
   PubMed Web of Science ®Google Scholar
• Gimbel M, Qaderdan K, Willemsen L, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet. 2020 Apr 25;395(10233):1374–1381. (London, England).
   PubMed Web of Science ®Google Scholar
• You SC, Rho Y, Bikdeli B, et al. Association of ticagrelor vs clopidogrel with net adverse clinical events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Jama. 2020;324(16):1640–1650.
   PubMed Web of Science ®Google Scholar
• Szummer K, Montez-Rath ME, Alfredsson J, et al. Comparison between ticagrelor and clopidogrel in elderly patients with an acute coronary syndrome: insights from the SWEDEHEART registry. Circulation. 2020 Nov 3;142(18):1700–1708.
   PubMed Web of Science ®Google Scholar
• Galli M, Capodanno D, Andreotti F, et al. Safety and efficacy of P2Y(12) inhibitor monotherapy in patients undergoing percutaneous coronary interventions. Expert Opin Drug Saf. 2020;30:1–13.
   Google Scholar
• Benenati S, Galli M, De Marzo V, et al. Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35,785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomised controlled trials. Eur Heart J Cardiovasc Pharmacother. 2021 Mar 15;7(2):86-93.
   Google Scholar
• Capodanno D, Mehran R, Valgimigli M, et al. Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nat Rev Cardiol. 2018 Aug;15(8):480–496.
   PubMed Web of Science ®Google Scholar
• Moon JY, Franchi F, Rollini F, et al. Evolution of coronary stent technology and implications for duration of dual antiplatelet therapy. Progress in Cardiovascular Diseases. 2018 Jan-Feb;60(4–5):478–490.
   PubMed Web of Science ®Google Scholar
• Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364(3):226–235.
   PubMed Web of Science ®Google Scholar
• Pilgrim T, Vranckx P, Valgimigli M, et al. Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction. Am Heart J. 2016 May;175:56–65.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ. Dual antiplatelet therapy guided by platelet function testing. Lancet. 2017 Oct 14;390(10104):1718–1720. (London, England).
   PubMed Web of Science ®Google Scholar
• Cavallari LH, Franchi F, Rollini F, et al. Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. J Transl Med. 2018 Apr 11;16(1):92.
   PubMedGoogle Scholar
• Empey PE, Stevenson JM, Tuteja S, et al. Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy. Clin Pharmacol Ther. 2018 Oct;104(4):664–674.
   PubMed Web of Science ®Google Scholar
• Cavallari LH, Weitzel KW, Elsey AR, et al. Institutional profile: university of Florida health personalized medicine program. Pharmacogenomics. 2017 Apr;18(5):421–426.
   PubMed Web of Science ®Google Scholar
• Saracini C, Vestrini A, Galora S, et al. Pharmacogenetics of clopidogrel: comparison between a standard and a rapid genetic testing. Genet Test Mol Biomarkers. 2012 Jun;16(6):500–503.
   PubMed Web of Science ®Google Scholar
• Chae H, Kim M, Koh YS, et al. Feasibility of a microarray-based point-of-care CYP2C19 genotyping test for predicting clopidogrel on-treatment platelet reactivity. Biomed Res Int. 2013;2013:154073.
   PubMed Web of Science ®Google Scholar
• Roberts JD, Wells GA, Le May MR, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet. 2012 May 5;379(9827):1705–1711. (London, England).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Capodanno D, Danchin N, et al. Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE Score. JACC Cardiovasc Interventions. 2020 Mar 9;13(5):606–617.
   PubMed Web of Science ®Google Scholar
• Koukouritaki SB, Manro JR, Marsh SA, et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther. 2004 Mar;308(3):965–974.
   PubMed Web of Science ®Google Scholar
• Li-Wan-Po A, Girard T, Farndon P, et al. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol. 2010;69(3):222–230.
   PubMed Web of Science ®Google Scholar
• Paré G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363(18):1704–1714.
   PubMed Web of Science ®Google Scholar
• Scott SA, Sangkuhl K, Shuldiner AR, et al. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genomics. 2012 Feb;22(2):159–165.
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Ingelman-Sundberg M, Miller NA, et al. The pharmacogene variation (pharmvar) consortium: incorporation of the human cytochrome P450 (CYP) Allele Nomenclature Database. Clin Pharmacol Ther. 2018 Mar;103(3):399–401.
   PubMed Web of Science ®Google Scholar
• Wedlund PJ. The CYP2C19 enzyme polymorphism. Pharmacology. 2000;61(3):174–183.
   PubMed Web of Science ®Google Scholar
• Pratt VM, Del Tredici AL, Hachad H, et al. Recommendations for clinical CYP2C19 genotyping allele selection: a report of the association for molecular pathology. J Mol Diagn. 2018 May;20(3):269–276.
   PubMed Web of Science ®Google Scholar
• Man M, Farmen M, Dumaual C, et al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to caucasians and Africans. J Clin Pharmacol. 2010 Aug;50(8):929–940.
   PubMed Web of Science ®Google Scholar
• Lewis JP, Stephens SH, Horenstein RB, et al. The CYP2C19*17 variant is not independently associated with clopidogrel response. J Thromb Haemost. 2013;11(9):1640–1646.
   PubMed Web of Science ®Google Scholar
• Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010 Oct 16;376(9749):1320–1328. (London, England).
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009 May 19;119(19):2553–2560.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Rollini F, Storey RF, et al. International expert consensus on switching platelet P2Y(12) receptor-inhibiting therapies. Circulation. 2017 Nov 14;136(20):1955–1975.
   PubMed Web of Science ®Google Scholar
• Benenati S, Crimi G, Canale C, et al. Duration of dual antiplatelet therapy and subsequent monotherapy type in patients undergoing drug eluting stent implantation: a network Meta-analysis. Eur Heart J Cardiovas pharmacol. 2020 Nov 2.
   PubMedGoogle Scholar
• Becker RC, Bassand JP, Budaj A, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2011 Dec;32(23):2933–2944.
   PubMed Web of Science ®Google Scholar
• Antman EM, Wiviott SD, Murphy SA, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction) analysis. J Am Coll Cardiol. 2008 May 27;51(21):2028–2033.
   PubMed Web of Science ®Google Scholar
• Deiman BA, Tonino PA, Kouhestani K, et al. Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands. Neth Heart J. 2016 Oct;24(10):589–599.
   PubMed Web of Science ®Google Scholar
• Chen S, Zhang Y, Wang L, et al. Effects of dual-dose clopidogrel, clopidogrel combined with tongxinluo capsule, and ticagrelor on patients with coronary heart disease and CYP2C19*2 gene mutation after Percutaneous Coronary Interventions (PCI). Med Sci Monit. 2017 Aug 7;23:3824–3830.
   PubMed Web of Science ®Google Scholar
• Lee CR, Sriramoju VB, Cervantes A. et al. Clinical outcomes and sustainability of using cyp2c19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. Circulation: Genomic and Precision Med. 2018;11(4):e002069.
   PubMed Web of Science ®Google Scholar
• Ogawa H, Isshiki T, Kimura T, et al. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. J Cardiol. 2016 Jul;68(1):29–36.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhao Y, Pang M, et al. High-dose clopidogrel versus ticagrelor for treatment of acute coronary syndromes after percutaneous coronary intervention in CYP2C19 intermediate or poor metabolizers: a prospective, randomized, open-label, single-centre trial. Acta Cardiol. 2016 Jun;71(3):309–316.
   PubMed Web of Science ®Google Scholar
• Cavallari LH, Lee CR, Beitelshees AL, et al. Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc Interventions. 2018 Jan 22;11(2):181–191.
   PubMed Web of Science ®Google Scholar
• Hulot J-S, Chevalier B, Belle L, et al. Routine CYP2C19 genotyping to adjust thienopyridine treatment after primary PCI for STEMI: results of the GIANT study. JACC Cardiovasc Interv. 2020 march 09;13(5):621–630.
   PubMed Web of Science ®Google Scholar
• Xie X, Ma YT, Yang YN, et al. Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial. Int J Cardiol. 2013 Oct 9;168(4):3736–3740.
   PubMed Web of Science ®Google Scholar
• Shen DL, Wang B, Bai J, et al. Clinical value of CYP2C19 genetic testing for guiding the antiplatelet therapy in a chinese population. J Cardiovasc Pharmacol. 2016 Mar;67(3):232–236.
   PubMed Web of Science ®Google Scholar
• Sánchez-Ramos J, Dávila-Fajardo CL, Toledo Frías P, et al. Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent. Int J Cardiol. 2016 Dec 15;225:289–295.
   PubMed Web of Science ®Google Scholar
• Notarangelo FM, Maglietta G, Bevilacqua P, et al. Pharmacogenomic approach to selecting antiplatelet therapy in patients with acute coronary syndromes: the PHARMCLO trial. J Am Coll Cardiol. 2018 May 1;71(17):1869–1877.
   PubMed Web of Science ®Google Scholar
• Tuteja S, Glick H, Matthai W, et al. Prospective CYP2C19 genotyping to guide antiplatelet therapy following percutaneous coronary intervention: a pragmatic randomized clinical trial. Circ Genom Precis Med. 2020 Feb;13(1):e002640.
   PubMed Web of Science ®Google Scholar
• Galli M, Benenati S, Capodanno D, et al. Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Lancet. 2021 Apr 17;397(10283):1470–1483.
   PubMed Web of Science ®Google Scholar
• Scott SA, Sangkuhl K, Stein CM, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317–323.
   PubMed Web of Science ®Google Scholar
• El Rouby N, Alrwisan A, Langaee T, et al. Clinical utility of pharmacogene panel-based testing in patients undergoing percutaneous coronary intervention. Clin Transl Sci. 2020 May;13(3):473–481.
   PubMed Web of Science ®Google Scholar
• Pereira NL, Rihal C, Lennon R, et al. Effect of CYP2C19 genotype on ischemic outcomes during oral P2Y(12) inhibitor therapy: a meta-analysis. JACC Cardiovasc Interventions. 2021 Apr 12;14(7):739–750.
   PubMed Web of Science ®Google Scholar
• Sibbing D, Kastrati A. Guided P2Y(12) inhibitor therapy after percutaneous coronary intervention. Lancet. 2021 Apr 17;397(10283):1423–1425. (London, England).
   PubMed Web of Science ®Google Scholar
• AlMukdad S, Elewa H, Al-Badriyeh D. Economic evaluations of CYP2C19 genotype-guided antiplatelet therapy compared to the universal use of antiplatelets in patients with acute coronary syndrome: a systematic review. J Cardiovasc Pharmacol Ther. 2020 May;25(3):201–211.
   PubMed Web of Science ®Google Scholar